Table I.
PK of rHEPO Following IV or SC Injection (Values Fitted to a Simple One-Compartment Model)
| Species | Dog (IU/kg) | Tmax (h) | T1/2 elimination (h) | %F | T1/2 absorption (h) | |
|---|---|---|---|---|---|---|
| IV | SC | |||||
| Dog | 500 (0.5 mL/kg) | 18.1 | 6.7 | 24.6 | 80.3 | 27.7 |
| Rat | 1,000 (1 mL/kg) | 12 | 13.8 | 12.6 | 76 | 5.4 |
| Mouse | 50 (10 mL/kg) | 7 | 11 | 17.7 | 73 | 0.8 |
| Mouse | 150 (10 mL/kg) | 3 | 7.7 | 9.7 | 68 | |
| Mana | (see note in legend) | 7.1 | 34.6 | 22.8 | ||
In all cases, serum concentration was corrected for background levels of endogenous erythropoietin. Animal results are compared against published information on the PK of this compound in humans. Based upon the information provided by Bleuel et al. (7). Note that in reviewing available information in the citations used to derive human dose, it would appear that most of the modeling was based upon doses of approximately 250 IU/kg or less
aWeighted average of means from 13 publications (original data and calculations not provided)